BTA
Click for more information
0.00% 57.0¢ biota holdings limited

fin review article

  1. terab
    171 Posts.
    clock Created with Sketch.
    17/01/10
    11:32
    Post #: 6211868
    Article in Fin Review Jan 16/17 2010
    *Biota Expects sales increase this year
    *Relenza royalties from Glaxo more than doubled in 2009
    *Glaxo intend to triple annual production this year
    *Governments worldwide are increasing their Relenza
    stockpiles.

    Very positive outlook for this year.
    BTA Price at posting: $2.01 Sentiment: ST Buy Disclosure: Held
    Likes Created with Sketch. 1  Upvote
    lightbulb Created with Sketch.  Great analysis
    Stroke 3 Created with Sketch. Comments Created with Sketch. Reply

  2. Top Stories

 

Featured News

BC8 Black Cat Syndicate one pour away from being rerated as producer
right-arrow Created with Sketch.
NEWS Training with professional athletes: How to invest like the best
right-arrow Created with Sketch.
IDA Indiana Resources to win US$90M from Tanzania following international lawsuit
right-arrow Created with Sketch.
DEG De Grey sees more production at Hemi with latest drilling at Crow, Aquila
right-arrow Created with Sketch.
NEWS Super PITch gold sponsor RSM Australia: Can Diggers & Dealers 2024 be key to reinvigorating IPO activity?
right-arrow Created with Sketch.
MTL Mantle Minerals' Nick Poll talks to HotCopper on finding gold grades up to 3.57g/t at Mt Berghaus
right-arrow Created with Sketch.
watchlist Created with Sketch. Add BTA (ASX) to my watchlist

Currently unlisted public company.

arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.